PYC Therapeutics Limited announced the submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) in support of its lead drug candidate known as VP-001. The FDA has a period of 30 days to review an IND application. In the event the IND is accepted, VP-001 will be the first investigational drug candidate with the potential to modify the course of Retinitis Pigmentosa type 11 to progress into clinical trials.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.095 AUD | -5.00% | -9.52% | -13.64% |
05-09 | Transcript : PYC Therapeutics Limited, Q2 2024 Earnings Call, May 09, 2024 | |
04-22 | Australian Shares Rebound Amid Easing Middle East Tensions, Ahead of Local Inflation Data | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.64% | 308M | |
+26.37% | 44.96B | |
-1.01% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.34% | 26.08B | |
-21.69% | 19.03B | |
+6.23% | 12.75B | |
+26.99% | 12.06B | |
-3.38% | 11.75B |
- Stock Market
- Equities
- PYC Stock
- News PYC Therapeutics Limited
- PYC Therapeutics Limited Announces the Submission of Investigational New Drug Application with the US Food and Drug Administration